T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 100 patients. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause non-small cell lung cancer (NSCLC) tumors to shrink and to see if this treatment is safe. Eligibility: \- Adults age 18-72 with NSCLC who have a tumor that can be safely removed. Design: * Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed * Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. * Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. {Leukapheresis is a common procedure, which removes only the white blood cells from the patient.} * Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits take up to 2 days.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-72 lata
- •Zaawansowany rak płuc (stadium IV) lub guz, którego nie można całkowicie usunąć chirurgicznie
- •Przynajmniej jeden guz, który można usunąć w celu pobrania komórek do leczenia
- •Co najmniej jedna poprzednia terapia systemowa, po której guz rósł
- •Dobry stan ogólny (ECOG 0 lub 1)
- •Jeśli przerzuty do mózgu - maksymalnie 3 poniżej 1 cm, bez objawów lub wyleczone
- •Gotowość do antykoncepcji przez 12 miesięcy po leczeniu (osoby w wieku rozrodczym)
- •Zdolność zrozumienia i podpisania zgody na udział w badaniu
✗ Disqualifies
- •Seropozytywny w teście HIV
- •Aktywny wirus zapalenia wątroby B lub antyciała przeciwko wirusowi zapalenia wątroby C
- •Liczba neutrofili poniżej 1000/mm³ bez wsparcia leków
- •Hemoglobina poniżej 8,0 g/dl
- •Liczba płytek krwi poniżej 80 000/mm³
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 72 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
NCI SB Immunotherapy Recruitment Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.